medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2008, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2008; 7 (1)


Liver biochemistry abnormalities in a quaternary care lipid clinic database

Wiesinger HAR; Shah J; White A; Yoshida EM; Frohlich J; Sirrs S; Gill S; Byrne MF

Idioma: Español
Referencias bibliográficas: 16
Paginas:
Archivo PDF: 115.36 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Farrell GC, CZ Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.

  2. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.

  3. Zieve FJ. The metabolic syndrome: diagnosis and treatment. Clinical Cornerstone 2004; 6(S3): S5-S13.

  4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.

  5. Stats Canada. Canadian Community Health Survey 2004.

  6. Kiyici M, Gulten M, Gurel S, Giray S, Doar E, Savci G, Adim SB, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003; 17: 713-18.

  7. Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, Karagiannopoulou G, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23: 131-4.

  8. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipidemic, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23: 11643-1647.

  9. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, et al. Ursoeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-7.

  10. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384(Lett).

  11. Chalasani, N. Statins and hepatotoxicity: focus on patients with fatty liver. Perspectives in Clinical Hepatology. 2005; 41: 690-5.

  12. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122; 1649-57.

  13. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-90.

  14. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33.

  15. Chalsani N, Gorski CJ, Craven R, Hall SD, Galinsky R. The effects of transjugular intrahepatic portasystemic shunts on the activity of cytochrome p450 3A in subjects with cirrhosis. Hepatology 2001; 34: 1103-8.

  16. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287-92.




2020     |     www.medigraphic.com